Drug Trial Radar · NCT00724815
The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
Last checked: Nov 19, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
530
Actual
Start
Jan 2009
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- NuPathe Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was a randomized, parallel group, double-blind, placebo controlled design to compare the efficacy and tolerability of NP101 to a placebo iontophoretic transdermal patch. The primary objective of this study was to assess the proportion of subjects who were headache pain free at two hours after patch activation. Key secondary objectives included: 1. The proportion of subjects who were nausea free at two hours after patch activation. 2. The proportion of subjects who were photophobia free at two hours after patch activation. 3. The proportion of subjects who were phonophobia free at two hours after patch activation.
Conditions
- Migraine Disorders
Interventions
NP101 - Sumatriptan iontophoretic transdermal patchDrug
Sumatriptan iontophoretic transdermal patch
PlaceboDrug
NP101 Placebo iontophoretic transdermal patch
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Free at Two HoursTime frame: 2 hours post patch activation
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Little Rock, Arkansas
Site not named
Newport Beach, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Fairfield, Connecticut
Site not named
Ocala, Florida
Site not named
Palm Beach Gardens, Florida
Site not named
Sunrise, Florida
Site not named
Atlanta, Georgia
Site not named
Columbus, Georgia
Site not named
Decatur, Georgia
Site not named
Savannah, Georgia
Site not named
Chicago, Illinois
Site not named
Ann Arbor, Michigan
Site not named
Kalamazoo, Michigan
Site not named
Springfield, Missouri
Site not named
St Louis, Missouri
Site not named
Mount Vernon, New York
Site not named
Plainview, New York
Site not named
Greensboro, North Carolina
Site not named
West Chester, Ohio
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Wynnewood, Pennsylvania
Site not named
Memphis, Tennessee
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Alexandria, Virginia
Site not named
Virginia Beach, Virginia
Site not named
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.